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Abstract
Molecular chaperones and co-chaperones, which are part of the protein quality control machinery, have been shown
to regulate distinct aspects of Alzheimer’s Disease (AD) pathology in multiple ways. Notably, the co-chaperone STI1,
which presents increased levels in AD, can protect mammalian neurons from amyloid-β toxicity in vitro and reduced
STI1 levels worsen Aβ toxicity in C. elegans. However, whether increased STI1 levels can protect neurons in vivo remains
unknown. We determined that overexpression of STI1 and/or Hsp90 protected C. elegans expressing Aβ(3–42) against
Aβ-mediated paralysis. Mammalian neurons were also protected by elevated levels of endogenous STI1 in vitro, and
this effect was mainly due to extracellular STI1. Surprisingly, in the 5xFAD mouse model of AD, by overexpressing STI1,
we find increased amyloid burden, which amplifies neurotoxicity and worsens spatial memory deficits in these
mutants. Increased levels of STI1 disturbed the expression of Aβ-regulating enzymes (BACE1 and MMP-2), suggesting
potential mechanisms by which amyloid burden is increased in mice. Notably, we observed that STI1 accumulates in
dense-core AD plaques in both 5xFAD mice and human brain tissue. Our findings suggest that elevated levels of STI1
contribute to Aβ accumulation, and that STI1 is deposited in AD plaques in mice and humans. We conclude that
despite the protective effects of STI1 in C. elegans and in mammalian cultured neurons, in vivo, the predominant effect
of elevated STI1 is deleterious in AD.
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Introduction
Alzheimer’s disease (AD), the most common cause of de-
mentia, afflicts close to 50 million people worldwide and
the number of affected individuals is projected to grow by
twofold every two decades [1]. Genetic mutations that
cause AD favour the abnormal processing of the amyloid
precursor protein (APP), from which the aggregation
prone amyloid-β (Aβ) peptide is derived [2–5]. In sporadic
and familial AD, Aβ peptides accumulate in soluble and
diffuse oligomeric forms and are deposited in insoluble
extracellular plaques. Over the past two decades it is be-
coming increasingly apparent that soluble oligomeric
forms of Aβ are a major toxin driving other pathologies
and inflammation in AD [6–14], supporting the “amyloid
hypothesis” [15, 16]. These small Aβ peptides attack neu-
rons causing neuronal dysfunction many years prior to the
appearance of cognitive symptoms, by interacting with
distinct neuronal proteins and receptors.
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One of the key receptors involved in Aβ toxicity is the
prion protein (PrPC), which interacts with Aβ oligomers
(AβOs) with high-affinity, and this interaction triggers me-
tabotropic glutamate receptor 5 (mGluR5) maladaptive
signalling in neurons [17–20]. PrPC functions as an extra-
cellular scaffolding protein that interacts with multiple li-
gands and receptors [21–23]. Specifically, Stress-inducible
phosphoprotein 1 (STI1, STIP1, or mammalian homolog:
Hsp organizing protein, HOP), a Hsp70/Hsp90 co-
chaperone, once secreted binds to PrPC, and protects
mouse neurons against a number of insults [24–28]. In
vitro, extracellular STI1 prevents toxic effects of AβOs, in-
cluding neuronal death and decreased long-term potenti-
ation, likely by interfering with AβO-PrPC interaction due
to contiguous binding sites for STI1 and AβOs along PrPC
[29]. Conversely, functional studies using a C. elegans
model of Aβ indicate that knockdown of Hsp90, STI1 and
several other co-chaperones increases Aβ toxicity [30].
Notably, STI1 has been identified in a genome-wide tran-
scriptome analysis as one of the top genes regulating ER
transcriptome stress response in the brains of sporadic
AD patients [31], and STI1 protein levels are upregulated
in AD patient brains [29].
In addition to interacting with PrPC, STI1 has a con-
served role as a co-chaperone for Hsp90 and Hsp70, and
disruption of STI1 function significantly interferes with
Hsp70/Hsp90 client expression and activity [25, 32–34].
STI1 overexpression rescued mutant huntingtin proteo-
toxicity in yeast by reorganizing cytotoxic huntingtin
into large high-molecular weight foci [35], suggesting
that increased STI1 levels could regulate amyloid aggre-
gation and lessen amyloid toxicity in mice by multiple
mechanisms. Molecular chaperones such as Hsp70 and
Hsp90 also play critical roles in AD and other protein
misfolding diseases [36–39]. In neurodegenerative dis-
eases, there is considerable evidence that molecular
chaperone complexes are altered [40] and Hsp90 inhib-
ition in vivo reduced neuronal and synaptic loss due to
amyloid toxicity in mice [41]. Moreover, blocking abnor-
mal chaperome interactions have also been shown to
improve tau toxicity [40].
Given that STI1 seems to prevent multiple proteotoxic
effects in yeast [35, 42, 43]), C. elegans [30, 44] and mam-
malian neurons [26, 28, 29, 45], we hypothesized that in-
creased STI1 levels can mitigate Aβ toxicity and
aggregation in vivo. We tested this assumption by modu-
lating levels of STI1 in a C. elegans model of Aβ toxicity,
in cultured mouse neurons, and by overexpressing STI1
(3-fold) in the 5xFAD mouse model of AD. In C. elegans,
STI1 and Hsp90 protected worms against Aβ-induced
paralysis. We also determined protection of cultured
mammalian neurons against AβOs by endogenous extra-
cellular STI1. In contrast, raising STI1 levels in mice amp-
lified the formation of extracellular Aβ plaques, which
increased neurodegeneration. Surprisingly, we found STI1
can accumulate in extracellular plaques in mice and it was
also found in mature plaques in humans. Our results sug-
gest a complex relationship between STI1 and amyloid
toxicity and indicate that some of the protective effects
observed in C. elegans may not directly translate to mam-
malian systems in vivo, due to the more complex mecha-
nisms of amyloidosis in the latter.
Materials and methods
Ethics statement
Animals were housed at The University of Western On-
tario vivarium and were managed and treated according
to the Canadian Council of Animal Care (CCAC) guide-
lines and Animal Use Protocols (2016–103, 2016–104).
Human tissue from autopsy of AD patients was obtained
with informed consent and approval from Office of Re-
search Ethics, Protocol 162656E at the University of
Western Ontario. Patients were assigned a neuropatho-
logical diagnosis by a licenced Neuropathologist certified
by the Royal College of Physicians and Surgeons of
Canada.
Nematode strains and growth conditions
C. elegans were grown on Nematode Growth Medium
(NGM) plates seeded with the E. coli OP50–1 strain and
cultured by standard methods [46]. The C. elegans strain
expressing Aβ(3–42) in the body wall muscle (CL2006
(dvIs2 [pcL12(unc-54/human Aβ peptide minigene) +
pRF4]) was obtained from the Caenorhabditis Genetics
Center. Strains overexpressing HSP-90 in the body wall
muscle (AM988 (rmIs347(unc-54p::HSP-90::RFP] [47]
and the strain overexpressing STI-1 in the muscle
(PPI1972 (unc-54p::STI-1::GFP); a kind gift of Dr. Anat
Ben-Zvi, Ben Gurion University, Israel) were crossed
into the genetic background of CL2006, resulting in
strains PVH50 (AM988 (rmIs347(unc-54p::HSP-90::RFP];
dvIs2), and PVH40 (PPI1972 (unc-54p::STI-1::GFP);
dvIs2), respectively. Overexpression of HSP-90 and STI-
1 together in the Aβ(3–42) expressing strain was achieved
by crossing strain AM988 into the genetic background
of PVH40, resulting in strain PVH71 (rmIs347(unc-54p::
HSP-90::RFP);(unc-54p::STI-1::GFP);dvIs2).
Paralysis assays
An age-synchronised population of 100 animals per
strain was scored by monitoring movement via the
touch-nose response, using a platinum wire. Animals
were transferred to fresh OP50–1 plates or indicated
RNAi plates every day. For paralysis assays on RNAi
plates, age-synchronised C. elegans were transferred onto
hsp-90 RNAi plates at L4 stage to avoid any develop-
mental effects, and onto sti-1 RNAi plates at L1 stage.
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Primary hippocampal neuronal cultures
Neuronal cultures from E17.5 WT control and TgA pups
were generated as described previously [29, 48]. Briefly,
hippocampi were separated from dissected brains clear of
meninges, and the cells were dissociated using 0.25%
trypsin-EDTA solution (ThermoFisher, Cat#25200056).
Approximately 4–6 × 104 cells were added to each well in
4-well plates (ThermoFisher, Cat#176740) pre-coated with
Poly-L-Lysine (Catalog# P6407, Sigma). Cells were plated
in Plating medium containing 10% heat inactivated fetal
bovine serum (Catalog# 12484–028, Gibco), 4.5% glucose
(Catalog# A2494001, Invitrogen), 1% Sodium Pyruvate
(Catalog# 11360070, Invitrogen), 1% Pen/Strep (Catalog#
11360070, Invitrogen) and 1% GlutaMAX (Catalog#
35050–161, Invitrogen) in MEM with Earle’s BSS (Catalog
# 11095, Invitrogen). After 4 h at 37 °C and 5% CO2, plat-
ing media was removed and replaced with complete Main-
tenance Medium (Neurobasal Medium, 1% Pen/Strep, 1%
GlutaMAX and 1% B27 supplement (Catalog# 17504044,
Gibco). Half of media were replaced with fresh medium
every 2 days and experiments were performed after 10–12
days in culture.
Cellular viability assays
AβO toxicity was assessed in hippocampal neuronal cul-
tures as described previously [17, 29, 48]. Briefly, neu-
rons were plated in 4-well dishes coated with Poly-L-
Lysine at a seeding density of 1 × 105. AβOs were added
to 10–12 day old cultures to the final concentration of
1 μM. After that cultures were incubated for 24–48 h at
37 C, 5% CO2, and the neuronal health was assessed by
various methods.
Lactate Dehydrogenase release was assessed in control
and TgA hippocampal neurons as described previously
[29] using Lactate Dehydrogenase (LDH) Activity Assay
Kit (Catalog # MAK066, Sigma). Briefly, neuronal cul-
tures were grown in a phenol red-free medium for 10
days, treated with AβOs for 24 h, after which the culture
media were collected and cleared by centrifuging for 20
min at 1000 x g and 4 °C. LDH activity was quantified by
measuring absorbance at 450 nm using BioRad iMark
Plate Reader.
LIVE/DEAD Viability/Cytotoxicity assay was per-
formed according to the manufacturer's instructions
(Cat#L3224, ThermoFisher). Briefly, 10–11 day old neur-
onal cultures were treated with AβOs with or without
anti-STI1 antibody (1:500, Bethyl Laboratories, [25]) for
48 h, after which the cells were washed with PBS and in-
cubated for 30 min in the dark with Calcein-AM and
Ethidium homodimer-1. Cultures were then immediately
imaged using 488 nm laser for excitation and 505/20
emmission filter for Calcein and 560/50 emmission filter
for Ethidium homodimer-1 using an LSM 510 Confocor
2 confocal microscope equipped with 10x /0.3 objective.
Mouse line generation and husbandry
STI1 overexpressing mice, TgA, were generated on a
C57BL6/J background as described previously [25, 49].
The 5xFAD Alzheimer’s disease mouse line (B6.Cg Tg
[APPSwFlLon,PSEN1*M146L*L286V] 6799Vas/J RRID:
MGI:034840-JAX) was obtained from The Jackson La-
boratory. Mice were crossed to generate TgA-5xFAD
and 5xFAD littermate progeny and maintained on a
mixed background of B6SJLF1/J and C57BL6/J, with no
further backcrossing. Male mice were used for behav-
ioural and immunohistochemical experiments because
previous characterization of TgA mice that was neces-
sary for this work was mainly done in male mice. Mice
used in experiments were given ad libitum access to
food (Harlan) and water. Mice were housed in standard
plexiglass cages with 2–4 littermates. Room temperature
and humidity were controlled at 22–25 °C and with 40–
60% respectively, and the light schedule followed a light/
dark cycle from 7 am-7 pm.
Preparation and purification of Aβ peptides
Aβ1–42 (rPeptide, Catalog# 1002) were prepared as
monomer films as described previously [29] and stored
desiccated at − 80 °C until use, for up to 2months. Olig-
omers were generated and characterized from Aβ1–42
films as described previously [29]. Briefly, peptide films
were thoroughly dissolved in DMSO to make a 1 mM
stock, after which the solution was diluted 10-fold in
Ham’s F12 Medium (Wisent), centrifuged for 10 min at
16,100 x g and then incubated for 24 h at 4 °C. Prepar-
ation quality was regularly checked by SDS-PAGE, prob-
ing with the anti-Aβ (6E10, BioLegend) antibody.
Oligomers and control preparations were either used
directly or frozen at − 80 °C in aliquots and used for up
to 4 weeks.
Morris water maze
The spatial Morris water maze (MWM) task was per-
formed as described previously [32, 49–51]. Seven to
eight WT (TgA--5xFAD-, one mouse excluded for rever-
sal phase of task), twelve 5xFAD and twelve TgA-5xFAD
male mice were used for behavioural analyses. No a
priori power estimates were used, but numbers were
chosen based on previous experiments following the
MWM protocol [32, 49–51]. We used 6-month-old mice
because in previous experiments 5xFAD male mice at
this age have been shown to cross the platform less, take
longer to find the platform and have spatial reference
memory deficits compared to WT C57BL6 controls [52].
Experiments were performed at 22–24 °C in a room
with two large lamps next to the pool illuminating the
room, and animals were acclimated for approximately
30 min before task initiation. Performance on the MWM
was recorded with ANY-Maze Software. The researcher
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was blind to genotypes during experiments, however,
analyses for reference memory, reversal memory and ac-
quisition of the task were not done blindly. Animals
were trained for four days, four trials per day, to find the
platform in the water tank. On the fifth day of testing
(probe trial), the platform was removed and the percent-
age of time during 60 s that a mouse spent in each quad-
rant was analyzed, and this is referred to as reference
memory/probe trial. Two days following the acquisition
and memory testing phase, animals started the reversal
phase of the task, in which the platform was moved to a
different quadrant. Learning to acquire the new position
of the platform was assessed again over four days, and
reversal memory after the platform was removed on the
fifth day was analyzed as described above.
Western blotting
After mice (3–5-month-old, male) were anesthetized with
ketamine (100mg/kg)-xylazine (20mg/kg), the animals
were perfused with ice cold PBS and one whole hemi-
sphere was collected for neuropathology (procedure de-
scribed below) and the other hemisphere was dissected for
Western Blotting or ELISA. Tissue was dissected on ice to
isolate cortex and hippocampus, then flash frozen on dry
ice before transferred to − 80 °C for long-term storage.
Western blotting was performed as described previously
[32, 49, 53]. Briefly, tissue was weighed and homogenized
in ice cold RIPA buffer (50mM Tris, 150mM NaCl, 0.1%
SDS, 0.5% Sodium Deoxycholate, 1% Triton-X 100, pH
8.0) with phosphatase inhibitors (1mM NaF and 0.1 mM
Na3VO4) and protease inhibitor cocktail (1:100, Catalog#
539134-1SET, Calbiochem), followed by cold sonication
3 × 7 s. Homogenates were then rocked at 4 °C for 20min,
then centrifuged at 10,000 x g for 20min at 4 °C to isolate
protein. Protein was quantified using BioRad DC Protein
assay (Catalog# 5000112, BioRad). 5–80 μg of protein
was loaded onto 4–12% Bis-Tris Plus Gels (Thermo-
Fisher) or on 13.5% Tris-Tricine Gels. Protein was
transferred onto PVDF membranes (Catalog #:
IVPH00010, EMD Millipore) by BioRad Semi-Dry
Transfer Trans-Blot Turbo system. Primary antibodies
used for immunoblotting: anti-STI1 (1:5000, in-house
antibody generated by Bethyl Laboratories Montgomery,
USA), anti-Hsp90β (1:1000, Cat#5087, Cell Signaling,
RRID:AB_10548761), anti-Hsp70 (1:1000, Cat#ab2787,
Abcam, RRID:AB_303300), anti-APP (C-terminal; 1:1000,
Cat#ab32136, Abcam, RRID:AB_2289606), anti-APP (N-
terminal; 1:1000, Cat#ab2072, Abcam, RRID:AB_302812),
anti-BACE1 (1:1000, Cat#5606, Cell Signaling, AB_
1903900), anti-MMP2 (1:1000, Cat#ab37150, Abcam,
RRID:AB_881512), Anti-CD10 (Neprilysin: 1:1000,
Cat#ab951, Abcam, RRID:AB_2146533), Anti-Insulin De-
grading Enzyme (1:1000, Cat#ab32216, Abcam, RRID:AB_
775686), anti-PSD95 (1:1000, Cat#MA1046, Pierce, RRID:
AB_2092361), anti-Synaptophysin (1:1000, Cat#5461, Cell
Signaling, RRID:AB_10698743). Loading control used was
anti-β-actin (1:25000, Cat#A3854, Sigma, RRID:AB_
262011) and secondary antibodies were sheep anti-mouse
HRP (1:5000, Cat#SAB3701095, Sigma, RRID: N/A) and
goat anti-rabbit HRP (1:10000, Cat#170–6515, BioRad,
RRID:AB_11125142). Proteins were visualized using
chemiluminescence on FluoroChemQ chemiluminescent
exposure system (Alpha Innotech) or ChemiDoc MP Im-
aging System (BioRad) and analyzed using their respective
software (Alpha Innotech and Image Lab).
Biochemical fractionation to isolate Tris-soluble,
membrane bound and insoluble APP
Tris-soluble, membrane-bound and insoluble fractions
were isolated as described previously [50, 54]. Cortices
from 3 to 5-month-old male mice perfused with ice cold
phosphate-buffered saline (PBS), pH 7.4, were used for
experiments. Tissue was weighed and homogenized
using Wheaton Overhead Stirrer (Cat#903475) in 6.5×
the weight of each sample in 20mM Tris-HCl (pH 8.5)
with protease and phosphatase inhibitors. Homogenates
were centrifuged for 1 h at 135,000 x g at 4 °C. Super-
natant was collected as Tris-soluble fraction and stored
for ELISA at − 80 °C. Next, tissue was homogenized and
resuspended in 10mM Tris, 150 mM NaCl, 0.02%
Triton-X 100 (pH 7.6) with protease and phosphatase in-
hibitors, 15× the weight of pellet, using Cordless Motor
and Pestle (Cat#47747–370, VWR). Samples were centri-
fuged at 100,000 x g for 1 h at 4 °C. Supernatant was col-
lected as the membrane-bound fraction and stored
immediately at − 80 °C for Western blotting. Finally, pel-
let was resuspended and homogenized in 1 ml of 3
M Guanidinium Hydrochloride (GHCl), 50 mM Tris
(pH 8.0) with protease inhibitors followed by vigorous
vortexing and overnight incubation on a tube rotator at
4 °C to dissolve pellet into solution. This constituted the
insoluble APP fraction, which was then stored at − 80 °C
for use in ELISA.
Human Aβ1–42 ELISA
ELISA for Tris-soluble and GHCl insoluble Aβ was per-
formed as described previously [50, 54, 55] following
manufacturer’s instructions (Catalog# KHB3441,
ThermoFisher).
Histological processing
After mice were anesthetized with ketamine (100 mg/
kg)-xylazine (20 mg/kg) and then transcardially perfused
with ice cold PBS (pH 7.4), one hemisphere was placed
in 4% paraformaldehyde for 24 h, then in 15, 20% then
30% sucrose for 24 h at 4 °C before being embedded in
OCT (Thermo Scientific Shandon Cryomatrix embed-
ding resin, Catalog # 67–690-06), frozen on dry ice then
Lackie et al. Acta Neuropathologica Communications           (2020) 8:143 Page 4 of 19
stored at − 80 °C. Frozen tissue blocks were acclimated
to − 20 °C for at least 30 mins prior to cryosectioning on
Leica CM350 or CM1950 Cryostat, and 30 μM sections
were collected and stored free floating in PBS + 0.02%
sodium azide at 4 °C until use.
Congo red
Free floating sagittal sections (30 μm) were mounted
onto SuperFrost Plus Slides (Fisher), dried at RT, then
stained following IHC World “Modified High pH Congo
Red Staining Protocol for Amyloid” [50]. Briefly, sections
were incubated in filtered 0.3% Congo Red Solution (dis-
solved in 80% ethanol with 1% sodium hydroxide) for
10 min in the dark. Sections were rinsed in distilled
water until water ran clear, followed by 10 dips in alka-
line alcohol (1% sodium hydroxide in 50% ethanol) solu-
tion, then water wash. Sections were counterstained in
Harris Hematoxylin (Cat#10143–610, VWR) for 45 s,
rinsed in water for 2 min and then rocked in tap water
with 5 drops of concentrated (14.5 M) ammonium hy-
droxide until sections turned blue. After another water
rinse, sections were dehydrated in 70, 95 and 100% etha-
nol, followed by two 100% xylene washes and slides were
cover-slipped using DPX mounting media (Catalog#
44581, Sigma). Sections were imaged using Zeiss Axios-
kop Optical Microscope at 20X magnification, with two
images captured sequentially (non-overlapping) along
the dentate gyrus (from the apex to the hilus/opening of
the blades), and one image each along the CA3, CA1
and subiculum. Sections were at least 120 μm apart, with
4–6 sections per animal being imaged and quantified.
Experimenters were blind to genotype during image col-
lection and analyses. Images were analyzed in Fiji (Ima-
geJ, NIH), using the same parameters for each image
and genotype. Images collected were converted to 8-bit,
background was subtracted to create a light background
and separate colours. Images were then deconvoluted
using the H-PAS colour deconvolution function to
analyze Congo Red staining more accurately. The per-
cent area was averaged across the whole hippocampus
(averaging the values obtained from each separate hippo-
campal sub-region) and then 4–6 sections per mouse
were averaged, with 4–5 mice per genotype.
Thioflavin S staining
Thioflavin staining was performed as described previ-
ously [54], following the AlzForum protocol (Alzforum
https://www.alzforum.org/protocols/thioflavin-s-stain-
ing) with some modifications. Briefly, mounted 30 μm
sagittal sections were incubated with 1% Thioflavin S
(dissolved in 50% ethanol) for 8 min in the dark at room
temperature. Upon removal of stain, sections were
washed twice with 80% ethanol, 3 min each, then once
with 95% ethanol for another 3 min. Sections were then
re-hydrated with three distilled water washes. Sections
were mounted using Immumount (Cat#9990412, Ther-
moScientific, Shandon) and imaged using LSM Meta
510 confocal microscope equipped with a 10X/0.3 Plan
Neofluar objective. One-two sequential (non-overlap-
ping) images along the dentate gyrus were captured, as
well as 1 image each of the CA3, CA1 and posterior
CA1/subiculum areas. For analyses, images were con-
verted to 8-bit in Fiji, then a deconvoluted thresholded
image was obtained with a white background and black
plaques. The percent area of the plaques was measured
using the Fiji Measure plugin, averaged across the whole
hippocampus (averaging the values obtained from each
separate hippocampal sub-region image), and then 4–6
sections per mouse of each genotype were averaged. Sec-
tions from 4 to 5 mice per genotype were used, and ex-
perimenters were blind to genotype during image
collection and analyses.
Silver staining
Silver staining was performed as described previously.
Using 6-well plates and net-wells, free-floating sections
were stained with the NeuroSilver™ staining kit II (Cata-
log#: PK301, FD NeuroTechnologies, Inc., Baltimore,
USA) following manufacturer’s instructions. This kit la-
bels degenerating neuronal bodies, processes and termi-
nals. Images were taken using Zeiss Axioskop Optical
Microscope at 20X magnification, with two images being
taken along the dentate gyrus, from the apex to the
hilus/opening of the blades, one image each of the CA3,
CA1 and subiculum. At least 4 sections from 4 to 5 ani-
mals/genotype were stained and sections selected were
at least 120 μm apart. Using ImageJ (Fiji) Software
(NIH), images were converted to 8 bit and thresholded
to make the silver particles black and background white
(Circularity of 0–0.65). Particles were numbered and av-
eraged for each animal. The same parameters were used
for each section, animal and both genotypes.
Immunofluorescence
Immunostaining for Aβ in mouse tissue was performed
as described previously [54]. Sagittal 30 μm sections were
mounted onto Superfrost Plus slides and after drying,
sections were boiled in 10 mM sodium citrate (pH 6.1)
for 20 min in antigen retriever at 95 °C, and then cooled
on ice to RT for 1 h. Sections were then washed twice
for 5 min in 1X Tris-buffered saline (TBS), pH 7.5. Next,
sections were permeabilized by incubating in 0.3%
Triton-X in TBS, pH 7.5, twice for 5 min and blocked in
2% horse serum (HS), 2% normal goat serum (NGS), 1%
BSA, 0.3% Triton-X in TBS, pH 7.5, for 90 min at room
temperature. Sections were then incubated with primary
antibody anti-β-amyloid (6E10, Cat#803001, 1:200, Bio-
legend) alone, or with anti-STI1 (Bethyl Laboratories, 1:
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400), anti-Iba1 (Cat#:019–19,741, 1:1000, Wako, RRID:
AB_839504) or anti-Hsp90β (Cat#5087, 1:50, Cell
Signaling, RRID:AB_10548761). The following day after
~ 18 h incubation with primary antibody at 4 °C, sections
were washed twice with TBS, 5 min each, then incubated
with secondary donkey anti-rabbit Alexa Fluor 647 (1:
500, Cat#A-31573, ThermoFisher) and/or goat anti-
mouse Alexa Fluor 488 (1:500, Catalog# A-11001, Ther-
moFisher) antibodies for 2.5–3.5 h at 4 °C. Sections were
washed three times with TBS then incubated with
Hoechst 33342 (Cat#62249, ThermoFisher) for 15 min,
rinsed three times, then mounted on slides using Immu-
mount. For STI1 labelling with Aβ, prior to nuclear la-
belling, sections were incubated with Vector
TrueVIEW™ Autofluorescence Quenching Kit (Cat#-
VECTSP8400, Vector) following manufacturer’s instruc-
tions. Immunofluorescent labelling for cleaved caspase-3
was performed as described previously [50]. Percent area
analyses for Aβ immunoreactivity across the whole
hippocampus were performed as described above for
Thioflavin S staining. Images were captured using Leica
TCS SP8 (Leica Microsystems Inc., Ontario, Canada)
confocal system at 10X objective (N.A. 0.4) for Aβ per-
cent area experiments, at 20X objective (N.A. of 0.75)
for CC-3 immunostaining, and at 63X (N.A. of 1.4) for
Aβ, STI1, Hsp90β and Iba1 imaging.
For analyses of Iba1+ microglia in contact with Aβ
plaques, two sequential non-overlapping images along
the dentate gyrus were captured, as well as 1 image of
the CA3, 1 image of the CA1 and 1 image of the poster-
ior CA1/subiculum. The number of microglia in each
field of view was counted, considering a total (those sur-
rounding/touching plaques and not associated (near/in
contact) with plaques), and those only in contact with
plaques. The number of Aβ plaques in each imaged sub-
field was counted. The sum number of plaque-
associated microglia (those with processes or cell body
seen touching plaque or no more than 10 μm from
plaque) averaged per section and the average number of
microglia around plaques were estimated. Images were
captured using the using Leica TCS SP8 (Leica Micro-
systems Inc., Ontario, Canada) confocal system (40X ob-
jective, N.A. of 1.3).
Human AD tissue and immunofluorescence
Blocks of parietal and temporal human brain tissue from
5 patients with a Neuropathological diagnosis of AD (all
Braak stage 5–6: 3 male/2 female, average age 82; 75 year
old (y/o) male, 88 y/o male, 89 y/o male, 80 y/o female,
82 y/o female), were embedded in paraffin and sections
were cut at 5 μm using Microm HM335E Microtome,
then deparaffinized using the Leica Autostainer XL. Sec-
tions were then left rocking in TBS, pH 7.6 for 2 h. Anti-
gen retrieval was performed by boiling sections at 95 °C
in 10mM citrate buffer + 0.05% Tween (pH 6.0) for 20
min then cooled on ice in the same buffer for 1 h. Add-
itionally, sections were incubated in 70% formic acid for
10 min then rinsed with 10% formic acid. Sections were
rinsed with water, washed twice with TBS for 5 min.
Next, tissue was permeabilized in TBS with 0.3% Triton
X-100 for 5 min, followed by a 1.5 h blocking at RT in
2% horse serum, 2% NGS, 1% BSA, 0.3% Triton X-100
in TBS. Sections were incubated overnight at 4 °C with
primary antibodies anti-STI1 (1:300, Bethyl) and anti-
6E10 (1:100, Biolegend) in 1% horse serum, 1% NGS,
0.5% BSA and 0.1% Triton X-100 in TBS. The following
day, sections were left at RT for ~ 2 h in primary anti-
body, then washed twice with TBS with 0.1% Triton X-
100, followed by incubation with secondary antibodies
donkey anti-rabbit Alexa Fluor 647 (Cat#A-31573, Ther-
moFisher, RRID:AB_2536183) and goat anti-mouse
Alexa Fluor 488 (Cat#A-11001, ThermoFisher, RRID:
AB_2534069). Sections were incubated with secondary
antibodies for 4 h at 4 °C, then washed three times with
TBS. After washing, the sections were then incubated
for 30 s with TrueBlack Lipofuscin Autofluorescence
Quencher according to manufacturer’s instructions
(Cat#10119–144, Biotium), rinsed three times with TBS,
and mounted on slides with Immumount. Images were
obtained using Olympus FV1000 confocal microscope at
63X (N.A. of 1.35) at 1.5–2.5X zoom. Representative im-
ages shown are all from the same magnification and
zoom.
Statistical analysis
For C. elegans experiments, all experiments were re-
peated at least three times (3 biological replicates). Data
are presented as mean values +/− SEM. p-values for two
group comparisons were calculated using student’s t-
test. (*) denotes p < 0.05; (**) denotes p < 0.01 and (***)
denotes p < 0.0001. To compare two independent popu-
lations (paralysis assays) p-values were calculated using
the Wilcoxon Mann-Whitney rank sum test. For mouse
pathology and Western blot experiments, data were ana-
lyzed using student’s t-test, except for APP processing in
which Two-Way ANOVA was used. For MWM Two-
Way ANOVA with Repeated Measures were used to
analyze datasets, with appropriate post-hoc analyses as
required. Prism 7 software was used for all statistical
analyses.
Results
STI1 and Hsp90 protect C. elegans and mouse primary
hippocampal neurons against Amyloid-β toxicity.
We have previously shown that treatment with recom-
binant STI1 can protect cultured neurons from AβO in-
duced cell death, by preventing AβO mal-adaptative
signalling via the prion protein [29]. To investigate whether
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increased endogenous expression of STI1 can protect
mammalian neurons from AβO toxicity, we derived pri-
mary hippocampal neuronal cultures from E17.5 mouse
wild-type (WT) control embryos and those endogenously
overexpressing STI1 (mouse line named TgA; overexpress-
ing STI1 3-fold [25]). The cultures were subjected to in-
creasing concentrations of AβOs for 48 h. At 0.5 μM and
1.0 μM of AβOs, neuronal cultures from TgA mice died
significantly less than control cultures (Fig. 1a, p = 0.025,
p = 0.019 for 0.5 μM and 1.0 μM, respectively), determined
using the Live/Dead Assay. Likewise, using the LDH assay,
TgA neuronal cultures released less LDH (indicator of
dying cells) than control neurons at 1.0 μM of AβOs (Fig.
1b, p = 0.0017). Since exogenous recombinant STI1 and
PrPC interaction blocks AβO toxicity [29], we tested
whether secreted STI1 in TgA primary neurons was re-
sponsible for increased neuronal resilience against AβOs.
We blocked extracellular STI1 signalling with a validated
STI1 antibody [25] and assessed neuronal survival in the
presence of AβOs using the Live/Dead Viability and
Toxicity kit. We found that treating control or TgA cul-
tures with the anti-STI1 antibody had no significant effect
on cell viability (Fig. 1c, p > 0.1), in cultures pre-treated with
1 μM AβOs, TgA neuronal cultures had significantly less
cell death than control cultures (Fig. 1c, p = 0.033). How-
ever, WT and TgA neurons treated with AβOs and the
Fig. 1 Overexpression of STI1 protects both C. elegans and primary hippocampal mouse neurons from Aβ-toxicity. a The average percent of dead cells
((# of dead cells)/(# of live + # of dead cells))× 100) in E17.5 primary hippocampal neuronal cultures from WT or TgA embryos. Cells were imaged in 4
well dishes from 8 random fields (N = 6 individual embryos/genotype). Dishes were treated with either no Aβ, 0.1, 0.5 or 1 μM AβOs for 48 h.
b Likewise, WT or TgA primary hippocampal neurons were treated with 0, 0.25, 0.5 or 1 μM for 48 h, and LDH release was measured using colorimetric
assay, read at 450 nm. N = 3–4 individual embryos for WT hippocampal cultures for each condition and N = 5 individual embryos per condition for TgA
hippocampal cultures. c Quantification of percentage of cell death in hippocampal neuronal cultures treated for 48 h with 1 μM scrambled Aβ control,
antibody against STI1 (1:500), AβO alone (1 μM) or dishes treated with both AβO (1 μM) and anti-STI1 (1:500). At least four individual embryos were
used for each condition and genotype. d Percentage of body paralysis over 10 days in nematodes expressing Aβ(3–42) (strain CL2006 (dvIs2 [pcL12(unc-
54/human Aβ peptide minigene) + pRF4]) in the bodywall muscle and treated with empty vector control RNAi (black triangle), sti-1 RNAi (black circle), or
hsp-90 RNAi (black square). e Percentage of paralysis in worms expressing Aβ(3–42) (black circle), Aβ(3–42) worms overexpressing HSP90 in body wall
(strain AM988 (rmIs347(unc-54p::HSP-90::RFP)) (black square), Aβ(3–42) worms overexpressing STI-1 in muscle cells (strain PVH40 (PPI1972 (unc-54p::STI-
1::GFP);dvIs2))) (black triangle) and Aβ(3–42) worms overexpressing both STI-1 and HSP-90 in the bodywall muscle (strain PVH71 (rmIs347(unc-54p::HSP-
90::RFP);(unc-54p::STI-1::GFP);dvIs2) (black stars). For C. elegans experiments, 100 age synchronized animals were used for analyses. For panels a and b,
data were analyzed using Two-Way ANOVA, with Sidak’s or Bonferroni’s post-hoc tests for multiple comparisons, respectively, comparing WT vs TgA
across the different concentrations of the AβOs. For both panels c and d, groups were analyzed using Wilcoxon statistics, comparing to Aβ(3–42)
expressing organisms. *p < 0.05, ** p < 0.01. All data are mean ± SEM. Raw data available for Figure 1: https://doi.org/10.6084/m9.figshare.12115614
Lackie et al. Acta Neuropathologica Communications           (2020) 8:143 Page 7 of 19
anti-STI1 antibody displayed elevated levels of cell death,
and TgA neurons were no longer resilient against AβO in-
sult (Fig. 1c, p > 0.1).
In addition to preventing toxic AβO signalling [29], STI1
can modulate proteostasis [32, 42]. In yeast, Hsp70 requires
STI1 for the reorganization of amyloid-like proteins into
toxicity buffering foci [35], and Hsp70 and Hsp90, which
are bridged by STI1, can decrease Aβ fibril formation and
aggregation [56]. Hence, to initially study STI1 and Hsp90
mediation of Aβ proteotoxicity, we used C. elegans, an or-
ganism that does not express the prion protein or its homo-
logues, but has been shown to require STI1 for protection
and reduction of amyloid aggregates [30].
Previous work has shown that knockdown of STI-1 and
HSP-90 in C. elegans increases Aβ toxicity [30]. We repeated
and expanded these experiments, and confirmed in C. ele-
gans expressing Aβ(3–42) that RNAi-mediated knockdown of
sti-1 or hsp-90 significantly reduced motility compared to
worms only expressing Aβ(3–42) over 10 days (Fig. 1d, p=
0.0195, p= 0.0078, for sti-1 and hsp-90, respectively). Next,
we tested whether overexpression of STI-1 and HSP-90 in
worms could reduce Aβ-induced paralysis. We found that
worms overexpressing HSP-90 seven-fold (C. elegans
homolog: DAF-21/HSP-90,Aβ(3–42); HSP-90::RFP) were
less paralysed than Aβ(3–42) worms (Fig. 1e, p = 0.016).
Furthermore, worms overexpressing STI-1 two-fold
(Aβ(3–42); STI-1::GFP) displayed decreased levels of
paralysis (46% vs 23% at day 8, p = 0.016, Fig. 1e).
Interestingly, overexpression of both HSP-90 (7-fold)
and STI-1 (2 fold; Aβ(3–42); STI-1::GFP; HSP-90::RFP)
alleviated paralysis to a similar degree as overexpres-
sion of STI-1 alone (46% vs 27% at day 8, p = 0.016),
and showed a lesser effect than overexpression of
HSP-90 by itself. Hence, in a genetic worm model of
Aβ toxicity, both STI-1 and HSP-90 have protective
effects, although their effects were not synergistic.
Elevated amyloid deposition in 5xFAD mice
overexpressing STI1
To test whether the observations from cultured neurons
and C. elegans occur in vivo in an AD model, we crossed
the 5xFAD mouse line with the STI1 overexpressing mice,
TgA. We compared the changes in TgA-5xFAD mice with
their littermate controls 5xFAD for all subsequent experi-
ments. We first confirmed that STI1 was indeed overex-
pressed 3-fold as previously reported in the original TgA
line (Fig. 2). Similar to what we observed in the original
TgA mice (C57BL/6 background) [49], the constitutive
Hsp90 isoform, Hsp90β, was increased in the TgA-5xFAD
mice in comparison to 5xFAD littermate controls (Fig. 2a,
Fig. 2 Elevated levels of STI1 and Hsp90β in STI1 overexpressing 5xFAD mice (TgA-5xFAD). a Representative immunoblots from hippocampal
lysates obtained from 3 to 5-month-old male 5xFAD and TgA-5xFAD mice for STI1. b Protein levels of STI1 relative to actin and normalized to
5xFAD control. c Representative immunoblots and quantification from hippocampal lysates obtained from 3 to 5-month-old male 5xFAD and
TgA-5xFAD mice for d Hsp90β (previously shown to be increased in plain TgA mice) e and Hsp70. All data are mean ± SEM and were analyzed
using unpaired t-test. At least 5 mice were used for each genotype. Experiments were repeated at least twice. *p < 0.05, **p < 0.01, ***p < 0.0001.
Raw data available at: https://doi.org/10.6084/m9.figshare.12115704
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b, p < 0.0001, Fig. 2c, d, p = 0.027). The elevated levels of
Hsp90 are likely a compensatory response to increased
STI1 levels [49], supporting a strong genetic relationship
between Hsp90 and STI1 [57]. Moreover, we found no
difference in Hsp70 protein levels between 5xFAD and
TgA-5xFAD mice (Fig. 2c, e, p > 0.1).
We then tested whether STI1 overexpression would
affect Aβ deposition in 5xFAD mice. Since Hsp90 and
Hsp70 reduce Aβ fibrillization [56] and concerted
Hsp70-STI1 reorganizes diffuse amyloid [35], we pre-
dicted that overexpressing STI1 would reduce Aβ aggre-
gation and toxicity. We first evaluated amyloidosis using
Congo Red (labelling β-pleated sheets in amyloid fibrils
[58]), and Thioflavin S (labelling β-pleated sheets in
amyloid fibrils and extracellular neuritic plaques, [59]).
Surprisingly, we detected two-fold increase in Congo red
amyloid labelling in the hippocampi of 3–5-month-old
TgA-5xFAD male mice compared to 5xFAD mice
(Fig. 3a, b, p = 0.05). Likewise, when we examined Thio-
flavin S staining, there was significantly more amyloid
deposition in the hippocampi of TgA-5xFAD mice (Fig.
3c, d, p = 0.032). Moreover, Aβ immunoreactivity in
TgA-5xFAD mice, detected using an anti-Aβ antibody
(6E10, which also labels APP, intracellular and extracel-
lular amyloid), was double that of 5xFAD mice (Fig. 3e,
f, p = 0.047). We further evaluated the degree of Aβ ac-
cumulation in 5xFAD and TgA-5xFAD cortices using
ELISA against Human Aβ1–42. We performed these ana-
lyses in the cortex, since both the cortex and hippocam-
pus show considerable Aβ accumulation by 3–5months
of age in 5xFAD mice [60]. In congruence with the Aβ
stains and immunolabelling in hippocampi, we detected
an increase in GHCl insoluble Aβ, but not Tris-Soluble
Aβ1–42 levels (p > 0.14 for soluble and p = 0.0020 for in-
soluble, Fig. 3g, h) in TgA-5xFAD male mice compared
to 5xFAD controls. Surprisingly, these experiments sug-
gest that STI1 overexpression combined with the in-
crease in Hsp90 levels were linked to early accumulation
of Aβ insoluble plaques and augmented levels of insol-
uble amyloid.
Reduced neuronal resilience in 5xFAD mice
overexpressing STI1
Aggregation of Aβ in plaques has been proposed to se-
quester more toxic and soluble Aβ species and serve as a
reservoir of inert proteins [61, 62]. Given that in primary
hippocampal neurons STI1 is neuroprotective and re-
duces AβO-mediated toxicity (Fig. 1 and [29]) and C.
elegans experiments showed that STI1 prevented Aβ
toxicity in body wall muscle, we performed a number of
assays to assess whether 3–5-month-old TgA-5xFAD
mice present increased resilience to Aβ-toxicity. Firstly,
we used the FD NeuroSilver staining kit, which labels
degenerating neurons (axons and soma) [50, 63–66]. In
the hippocampi of male mice, we found significantly
more silver particles in TgA-5xFAD mice, compared to
their 5xFAD controls (Fig. 4a, b, p = 0.033), suggesting
that STI1 did not confer protection. Synapse loss is also
a consequence of Aβ oligomerization and aggregation,
thus we evaluated the levels of synaptic proteins, such as
the post-synaptic density marker PSD95, and the pre-
synaptic marker synaptophysin [60, 67]. PSD95 was
Fig. 3 Increased amyloidosis in young male 5xFAD mice overexpressing Hsp90 co-chaperone STI1. a Representative brightfield micrographs of
Congo Red labelling in the CA1/Subiculum, at 10X magnification and b quantification of average area fraction (% area) of Congo Red staining
across the whole hippocampus in 3–5-month-old male 5xFAD and TgA-5xFAD mice. Black arrows indicate plaques labelled with Congo Red. On
each graph, black circles represent individual 5xFAD mice and black squares are individual TgA-5xFAD mice. c Thioflavin-S staining representative
images from CA1/Subiculum hippocampal subfield and d, quantification of average percent area of the whole hippocampus with Thioflavin S
staining. e Aβ (6E10 antibody, Biolegend) immunoreactivity in CA1/Subiculum and f quantification of average percent area across the whole
hippocampus with Aβ immunofluorescence. Concentration (ng/mg) of Tris Soluble g, and GHCl Insoluble h, Human Aβ1–42 in cortex (1
hemisphere) from 3 to 5-month old 5xFAD and TgA-5xFAD male mice. All scale bars = 25 μm. Data are presented as mean ± SEM, and
experiments were analyzed using unpaired t-test. *p < 0.05, ** p < 0.01. Raw data available at: https://doi.org/10.6084/m9.figshare.12115713
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reduced by 50% in TgA-5xFAD hippocampal tissue
(Fig. 4c, d, p = 0.023), however no significant changes
were detected between genotypes for synaptophysin at
this age (Fig. 4c, e, p > 0.1). Cleaved caspase-3 immu-
noreactivity was also two-fold higher in the whole
hippocampus of TgA-5xFAD mice when compared to
littermate 5xFAD mice (Fig. 4f, g, p = 0.002). Taken
together, elevation of STI1 (combined with Hsp90)
was not neuroprotective, but rather these results sug-
gest increased accumulation of Aβ and plaque depos-
ition heightened downstream toxicity.
Given the findings that TgA-5xFAD mice have higher
levels of amyloid burden and neurotoxicity compared to lit-
termate 5xFAD mice, we next sought to determine if there
were any behavioural consequences. We addressed this by
assessing mouse learning and memory in the
hippocampus-dependent spatial MWM task. We used 6-
month-old mice and found no significant differences be-
tween genotypes (wild type (WT) of mixed B6SJL/C57BL6/
J background vs 5xFAD vs TgA-5xFAD) on time to find
platform (p > 0.1), distance travelled to platform (p > 0.1),
mean speed travelled (p > 0.1), or efficiency of path traveled
to platform (p > 0.1) during the learning phase of the
MWM. During the probe trial, which assesses spatial refer-
ence memory, WT and 5xFAD mice spend more time in
the target quadrant (Fig. 4h, p < 0.001 for both WT and
5xFAD comparisons of T vs O vs L vs R) and there was no
significant difference between time spent in target quadrant
between 5xFAD and WT mice (Fig. 4h, p > 0.1), suggesting
that at this age the mixed background 5xFAD mice used
here did not yet present deficits in reference memory. A
similar result was previously reported by Schneider et al.
[68] when examining 6-month-old 5xFAD male mice. In
contrast, TgA-5xFAD mice did not show preference for the
target quadrant (T vs O p = 0.076, whereas T vs L or T vs R
p > 0.1), and these mice spent significantly less time than
WT and (p = 0.011) and 5xFAD mice (p = 0.043) in the tar-
get quadrant. Hence, TgA-5xFAD mice have worse spatial
memory than 5xFAD mice. We then performed the rever-
sal component of the task, which assesses behavioural flexi-
bility. This entails changing the target quadrant where the
escaping platform is located, training the mice for an
Fig. 4 Increased neurodegeneration and memory deficits in 5xFAD mice overexpressing STI1. a Silver staining representative images (20X
magnification) in the CA1 of the hippocampus of 3–5-month old 5xFAD and TgA-5xFAD male mice. Scale bar = 50 μm. b Quantification of number of
silver particles (analyzed from thresholded image) across the whole hippocampus in 5xFAD and TgA-5xFAD mice. Three-four sagittal sections from at
least four 5xFAD or TgA-5xFAD mice were used for all staining and immunostaining experiments. Black circles depict individual 5xFAD mice and black
squares represent individual TgA-5xFAD mice. c Relative protein expression of synaptic markers PSD95 and synaptophysin in cortical lysates from 3 to
5-month old 5xFAD and TgA-5xFAD male mice and d, e densitometric quantification, normalized to actin loading control. f Cleaved caspase-3 (CC-3)
representative images in the CA1 of the hippocampus (scale bars, 25 μm) and g, quantification of CC-3 immunofluorescence, presented as average
percent area across the hippocampus. Data are presented as mean ± SEM, and data presented in b, d, g, e were analyzed using unpaired t-test.
*p < 0.05, ** p < 0.01. h Mice were trained for four days on the spatial Morris Water Maze. On the fifth day (Probe trial), the target platform was
removed and memory for what quadrant of the pool the target platform was placed, was quantified as the percentage of time in each quadrant. This
was assessed in WT (TgA−-5xFAD−, n = 7), 5xFAD (n = 12) and TgA-5xFAD (n = 12) mice. i Two days following the Probe trial, animals were put on the
“reversal” phase of the task, in which the target platform was placed in a different quadrant. Animals were trained for four days then memory was
probed again and is denoted as the Reversal: Probe. T = Target, O = quadrant Opposite to target quadrant, L = quadrant to the Left of the target
quadrant, R = quadrant to the Right of the target quadrant. All MWM data were analyzed using Two-Way Repeated Measures ANOVA with appropriate
Tukey’s post hoc multiple comparisons. The * symbols in h, i represent Tukey’s post hoc multiple comparisons analysis, comparing percent time spent
in the target quadrant (T) comparing the O, L, or R quadrants, within each genotype. *p < 0.05, ** p < 0.01, *** p < 0.0001 for within genotype
comparisons for the MWM task. Raw data available at: https://doi.org/10.6084/m9.figshare.12115716
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additional 4 days, and then re-probing the memory on the
fifth day for the new target quadrant. In this reversal task,
when compared to WT control mice, both 5xFAD mice
and TgA-5xFAD mice spent less time in the target quad-
rant than controls (Fig. 4i, p = 0.03 and p = 0.029, respect-
ively), with no difference between 5xFAD and TgA-5xFAD
mice (p > 0.1). These results demonstrate that both 5xFAD
and TgA-5xFAD mice have deficits in behavioural flexibility
in comparison to WT control mice. Interestingly, when
preference for the target quadrant was evaluated, both
5xFAD and TgA-5xFAD mice showed increased preference
for target quadrant compared to the opposite and right
quadrant, suggesting that increased training potentially
helped these mutants to solve the task.
Unaltered APP processing but differential expression of
enzymes involved in Aβ-degradation
The elevated levels of insoluble Aβ and acceleration of
plaque pathology due to increased STI1 levels may be
caused by a number of factors. These include increased
APP levels, changes in APP metabolites, changes in the
enzymes or processes involved in Aβ metabolism, de-
creased degradation of Aβ, or a combination of these
factors. Given the diverse roles of intracellular and extra-
cellular STI1 and Hsp90, it is conceivable that more than
one mechanism is required to increase insoluble Aβ. We
evaluated the levels of full-length APP in the membrane
bound fraction and found no difference between geno-
types for full-length APP, or α and β C-terminal frag-
ments (Fig. 5a, b, p > 0.1), suggesting that the increased
amyloid deposition observed in Fig. 3 is not due to in-
creased APP levels or processing. In contrast, the levels
of enzymes known to regulate Aβ cleavage or degrad-
ation were affected by STI1 overexpression. The β-
secretase BACE1, the pro-amyloidogenic enzyme that
cleaves APP to form the β-CTF [69–71] was upregulated
three-fold in TgA-5xFAD mice compared to 5xFAD
mice (Fig. 5c, d, p = 0.016). We examined the levels of
BACE1 in WT vs TgA mice (C57BL/6 background) and
found that BACE1 was also significantly elevated in TgA
cortical lysates, however only by 1.5-fold (data not
shown). MMP-2, a matrix metalloproteinase known to
Fig. 5 Overexpression of STI1 in 5xFAD mice does not affect APP processing, however levels of Aβ regulating enzymes are altered. a
Representative Western blot for membrane bound full length APP and C-terminal APP fragments in cortices of 3–5-month old male 5xFAD and
TgA-5xFAD mice. b Densitometric quantification of C-terminal fragment protein levels relative to full length APP, presented as percentage of total
full-length APP [Signal intensity of the α or β fragment/signal intensity of full-length APP] × 100). At least 3 mice/genotype were used for
experiments. Data were analyzed with Two-way ANOVA with Sidak’s post-hoc comparisons. On each graph, black circles represent individual
5xFAD mice and black squares are individual TgA-5xFAD mice. c Protein levels of BACE1 in cortical tissue from 3 to 5-month old 5xFAD and TgA-
5xFAD mice and d, densitometric analysis. e Representative immunoblot and quantification f, for Aβ-degrading enzyme, matrix-
metalloproteinase-2 (MMP-2). g Representative immunoblot and h quantification, for Aβ-degrading enzyme neprilysin. i Representative
immunoblot and j quantification, for Aβ-degrading enzyme, Insulin-degrading enzyme (IDE). For C-J, N = 5 mice/genotype. Data are presented as
mean ± SEM. Experiments were analyzed using unpaired t-test. *p < 0.05. Raw data available at: https://doi.org/10.6084/m9.figshare.12115758
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interact with both Hsp90 and STI1 [72, 73] can degrade
Aβ, and overexpression of this protein lessened amyloid
burden in 5xFAD mice [74]. We found a 50% reduction in
MMP-2 protein levels (antibody for pro and activated
forms of MMP-2) in TgA-5xFAD mice compared to
5xFAD controls (Fig. 5e, f, p = 0.0026). Neprilysin, a well-
studied Aβ-degrading enzyme, that is reduced in the
hippocampus and cortex of AD mice and humans [75,
76], was slightly increased in TgA-5xFAD mice by about
1.5-fold, compared to 5xFAD controls (Fig. 5g, h, p =
0.018). Lastly, we measured protein levels of insulin-
degrading enzyme – which is proposed to have
chaperone-like activity when degrading Aβ-peptides [77,
78], and found no difference between TgA-5xFAD and
5xFAD mice (Fig. 5i, j, p > 0.1). These results suggest mul-
tiple changes in levels of proteins that participate in amyl-
oid generation and degradation could lead to increased
production or decreased clearance of Aβ due to increased
STI1 (with the compensatory increase in Hsp90β as well).
Another mechanism by which amyloid peptides are
degraded, is clearance by microglia [79, 80]. We ad-
dressed whether 3–5-month-old TgA-5xFAD mice could
present altered levels of microglia in contact with pla-
ques, since microglia are known to phagocytose Aβ [79,
81, 82]. Immunostaining of brain tissue for microglia
(Iba1) [83] and Aβ ([6E10, (Fig. 6a)] revealed that a
significantly higher number of microglia were closely as-
sociated with plaques across the whole hippocampus in
TgA-5xFAD vs 5xFAD mice (Fig. 6b, p = 0.023), likely
due to the presence of more plaques in TgA-5xFAD
mice (representative images of dentate gyrus and subicu-
lum shown in Fig. 6a). However, the average number of
microglia in contact with an individual plaque did not
differ between 5xFAD and TgA-5xFAD mice (Fig. 6c,
p > 0.1). Relative to neurons, microglia express very low
levels of STI1 and Hsp90, as revealed by single-cell
RNAseq [84], thus our results suggest that increased
levels of STI1 did not impact microgliosis around pla-
ques and that the increased deposition of Aβ is not due
to decreased microglia in contact with plaques.
Accumulation of extracellular STI1 and Hsp90 around Aβ
dense core, senile plaques
The above experiments suggest that STI1 potentially fa-
vours increased production and decreased degradation of
Aβ, given the increase in BACE1 and decreased levels of
enzymes that can degrade amyloid. STI1, Hsp70 and
Hsp90 are secreted by a variety of cells and they are found
in the extracellular milieu [25, 85–87], plasma [88] and in
principle they could directly contribute to the regulation
of Aβ aggregation. Notably, glia secreted Hsp70 reduces
neuronal stress in LA-N-5 neuroblastoma cells [89],
Fig. 6 Microgliosis in the hippocampi of TgA-5xFAD mice. a Representative confocal micrographs from the dentate gyrus (DG) and subiculum
immunolabelled for Aβ (anti-6E10) and microglial marker Iba1. Analyses b & c are from 5 individual mice with four sections being imaged per
mouse at 40X magnification using confocal microscopy. Two images along the DG, one along the CA3, one along the CA1 and one in the
subiculum were analyzed for number of plaques, number of microglia and number of microglia around plaques. b Quantification of the sum
(average across sections and mice) number of microglia in contact with plaques across the whole hippocampus. c Quantification of the average
number of microglia in contact with each plaque across all subfields. Scale bars = 50 μm. Data are presented as mean ± SEM. Experiments were
analyzed using unpaired t-test. *p < 0.05. Raw data available at: https://doi.org/10.6084/m9.figshare.12115782
Lackie et al. Acta Neuropathologica Communications           (2020) 8:143 Page 12 of 19
reduces Aβ toxicity in Drosophila [90], and extracellular
Hsp70 lessens Aβ-oligomerization and attenuates Aβ tox-
icity in N2A cells [91]. Moreover, Hsp90 has been previ-
ously shown to decrease Aβ fibrillization in vitro [56, 92].
These results may suggest that STI1 could be closely asso-
ciated with plaques, which we tested by using immuno-
fluorescence confocal microscopy. We performed
unbiased, random imaging of STI1 and Aβ plaques in the
hippocampus and cortex of 3–5-month-old 5xFAD and
TgA-5xFAD mice. We observed STI1 around the dense
core of Aβ plaques (anti-6E10 antibody), representing a
ring-like structure in both 5xFAD and TgA-5xFAD mice
(Fig. 7a). STI1 around plaques did not seem to be located
in microglia (Fig. 7c), as there is little colocalization be-
tween STI1 staining and Iba1+ glial cells, or nuclear
marker DAPI (Fig. 7a-c). STI1 co-localization with the Aβ
immunoreactive neuritic plaques/cored plaques can be
observed in both 5xFAD and TgA-5xFAD mice in
both the cortex and hippocampus (Fig. 7a, b), but it
is more prominent in TgA-5xFAD. Likewise, we ob-
served co-localization of Hsp90β with dense-core pla-
ques, in both 5xFAD and, increasingly more
discernable, in TgA-5xFAD mice (Fig. 7d). These re-
sults suggest that extracellular STI1 and Hsp90β can
accumulate in Aβ plaques.
Importantly, we verified that STI1 is also present in
plaques in human AD brains. Immunofluorescence im-
aging of STI1 and Aβ in five AD patient brains showed
significant STI1 labeling in what seemed to be more ma-
ture plaques (a minimum of 5 found in each section)
with dense cores of Aβ (Fig. 8a; a minimum of 3 distinct
sections labelled and plaques imaged). Conversely, we
also observed several examples of less mature plaques
(at least 10–20 per brain section) in which STI1 was not
accumulated (Fig. 8b). Blood vessels that were positive
for Aβ also showed STI1 immunoreactivity (small white
filled arrow in Fig. 8a).
Discussion
The present experiments revealed the relationship be-
tween STI1 and Hsp90 in worm and mouse AD models
of amyloidosis in vivo. We confirmed and extended pre-
vious results demonstrating that in cultured neurons,
overexpression of STI1 prevented Aβ toxicity via extra-
cellular mechanisms. We also report an inverse relation-
ship between levels of Hsp90, STI1 and Aβ toxicity in
worms, suggesting that increasing the levels of Hsp90
and STI1 is protective.
In contrast, in mammals, endogenous elevation of
STI1 and compensatory ectopic increase in Hsp90β
Fig. 7 Extracellular STI1 deposits are found in dense core and neuritic plaques in 5xFAD mice. a Representative confocal images (63X
magnification) of Aβ (anti-6E10, green), STI1 (red) and nuclei labelled with DAPI (blue) in the CA1 region of the hippocampus of 3–5-month old
male 5xFAD and TgA-5xFAD mice. Images are Z-stack projections composed of images including Aβ plaques. White arrows indicate areas where
extracellular STI1 is visualized within the Aβ deposits around the core of the plaque. Scale bars = 25 μm. b Aβ plaques and STI1 immunolabelling
in the cortex of 3–5-month old 5xFAD and TgA-5xFAD male mice. Scale bars = 25 μm. c Aβ (6E10, green), STI1 (blue) and Iba1 microglial marker
(red) labelling in the subiculum of 3–5-month old male 5xFAD and TgA-5xFAD mice. White arrows indicate areas where extracellular STI1 is
visualized within the Aβ deposits around the core of the plaque. d Representative images of tissue labelled with DAPI (blue) Aβ (6E10, green),
Hsp90β (red) in the cortex of 3–5-month old male 5xFAD and TgA-5xFAD mice. White arrowheads indicate areas where extracellular Hsp90β
deposits are colocalizing within plaques. Three-four sagittal sections from at least three 5xFAD or TgA-5xFAD mice were used for all
immunostaining experiments. Scale bars = 25 μm
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resulted in much more complex effects in vivo. In gen-
eral, we show that increasing STI1 and Hsp90 levels in
mice overexpressing human APP with mutations that
favour the generation of toxic Aβ peptides (5xFAD), es-
calated the accumulation of insoluble protein aggregates.
Importantly, measures of cellular toxicity in brain tissue,
and mouse behavioral tests suggest that increased insol-
uble Aβ plaque burden are linked to worse outcome in
TgA-5xFAD mice. However, given the resulting increase
of Hsp90 due to overexpression of STI1, it remains un-
known if overexpression of Hsp90β alone in 5xFAD
mice would lead to the same increase in amyloid burden
or impact levels of STI1 in vivo. In vitro neuronal assays
with recombinant Hsp90 and STI1 by Maciejewski et al.
[48] revealed that surplus addition of Hsp90 in the pres-
ence of increasing concentrations of STI1 prevented
STI1 neuroprotection against AβOs. These results sug-
gest that excessive levels of Hsp90 interferes with STI1
binding to PrPC, which could explain why more neuro-
degeneration was found in TgA-5xFAD mice.
Different types of Aβ aggregates may act in different
ways to affect neurons. Numerous recent experiments
have focused on the toxicity of Aβ oligomers and dem-
onstrated that these toxic species interact with the prion
protein to trigger maladaptive neuronal signalling [19,
29, 93–95]. In vitro data suggest that extracellular STI1
is beneficial for neurons either by leading to increased
protein translation [96], neuritogenesis [26], or protect-
ing neurons against a number of chemical or environ-
mental insults [25, 26, 28]. Indeed, we found that
secreted STI1 by TgA neurons was responsible for the
enhanced resilience against AβOs, since blocking STI1
with an anti-STI1 antibody abolished this protection.
In addition to the toxic effects of AβOs, the accumula-
tion of insoluble forms of Aβ can trigger ER stress [54,
97–99] and burden cellular protein quality control.
Interestingly, transcriptomic analyses of AD patients’
brains identified STI1 as a regulator of the unfolded pro-
tein response [31]. In yeast, which have highly conserved
STI1 and Hsp90 genes, STI1 activity seems to be vulner-
able to excessive amounts of accumulated exogenous
proteins [42], which then disturbs chaperone network
activity. Moreover, increased levels of STI1 decreased
amyloid toxicity in yeast, by regulating their spatial dis-
tribution and toxic assembly [35]. These results suggest
that increasing the levels of STI1 and Hsp90 seem to
help certain organisms, such as yeast and worms, whose
Aβ is not secreted and remains intracellularly [35, 100]
to deal with the increased proteotoxicity of amyloid pro-
teins. Although our results in C. elegans, an organism
that does not have a homologue for the prion protein,
are in line with the in vitro experiments [29, 101], it is
clear that in mice the extracellular effects of STI1 via the
prion protein do not seem to be as relevant as other ac-
tions, such as STI1 modulation of proteostasis and pro-
tein aggregation.
STI1 and Hsp90 are secreted by a myriad of cells and
have the potential to be found extracellularly in the
mammalian brain [25, 85–87, 102]. Regulation of extra-
cellular Hsp90 by co-chaperones, and extracellular
Hsp90 chaperone activity is not well studied, but it was
recently found that extracellular Hsp90 is regulated by
co-chaperones Aha1 and TIMP2 to regulate their client
protein MMP-2 [103]. These results raise the possibility
that extracellular STI1 could indeed be regulating and
altering the Hsp70/Hsp90 machinery. Moreover, the in-
creased levels of STI1 and consequent increase in Hsp90
appear to contribute to augmented Aβ burden in mice
in different ways. The levels of BACE1 were increased
three-fold, whereas MMP-2, an important enzyme for
amyloid β degradation, and an Hsp90 client, was signifi-
cantly decreased. However, APP levels were not different
between 5xFAD and TgA-5xFAD mice. We detected no
evidence that microglia close to plaques were altered,
Fig. 8 Dense-core plaques in human Alzheimer’s patients have
extracellular STI1 deposits. a Representative images of mature dense
core Aβ plaques (63X) from five AD patients in temporal and parietal
cortex. b Representative images of diffuse Aβ plaques images from
five AD patients (63X). Green is for Aβ (anti-6E10), red for STI1. Scale
bars = 25 μm. Large white arrowhead show STI1 and Aβ
colocalization, small filled white arrowheads show STI1 + Aβ
immunoreactive blood vessels
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suggesting that increased STI1 levels may not affect this
mechanism of plaque removal.
There has been debate in the literature as to whether
amyloid plaques are indeed toxic or may be a means to
protect cells against Aβ-peptide and AβO toxicity [61,
62, 104, 105]. Our results show that the amplified amyl-
oid burden in TgA-5xFAD correlates with increased
neurodegeneration, post-synaptic density loss, increased
apoptosis, as well as worse performance of mice in the
spatial MWM. Hence, it seems that at least for the
5xFAD mouse line, the increase in plaques was not pro-
tective and Aβ oligomer toxicity does not play a major
role in the toxicity, given that this should be blocked by
extracellular STI1.
The role of Hsp70/Hsp90 and STI1 in other types
of protein misfolding diseases is starting to be inves-
tigated and warrants further analysis. Tau is a client
of Hsp90 and inhibition of Hsp90 to stimulate
Hsp90 re-folding pathway seems to favour degrad-
ation of overexpressed misfolded tau and phospho-
tau [106]. Hsp90 co-chaperones STI1, Hsp40, CHIP,
p23, and Pin1 were all necessary for mediating tau
re-folding and/or degradation. Furthermore, STI1/
Hop loss of function in Drosophila overexpressing
the full-length 2 N/4R isoform of wild-type human
tau in the eye, resulted in significant loss of retinal
cells [107]. Recently, Inda et al. [40] demonstrated
that in AD, chaperones associate to form large stable
complexes, termed epichaperomes, that no longer
regulate client protein function. These epichaper-
omes impaired protein connectivity, proteostasis, and
synaptic plasticity in their AD mouse models [40],
which could be corrected by disassembly of epicha-
peromes by an Hsp90 inhibitor. Since Hsp90, Hsp70
and STI1 are all members of these epichaperomes in
AD tissues, it may be important to test in the future
how increased or decreased levels of STI1 regulate
epichaperomes.
Hsp90, along with other small Hsps have been previ-
ously found to co-localize with Aβ plaques [80, 108–
111], however it is not fully elucidated whether this is a
result from cellular debris or if the plaques sequester
chaperones. We found STI1 and Hsp90 immunolabelling
in dense core and neuritic plaques – the type of plaques
that are associated with late stage AD and are typically
surrounded by glial cells [112]. Interestingly, we similarly
found that in AD patients, STI1 accumulates only within
the dense core of senile plaques. Deposits of chaperones
in protein aggregates may disturb chaperone function,
suggesting that molecular chaperone activity may be im-
paired in AD, potentially affecting a number of client
proteins.
In summary we found a striking difference between
the actions of Hsp90 and STI1 in C. elegans and in mice.
Overall, the observations presented here suggest a com-
plex relationship between Hsp90, STI1, and Aβ peptides
in mammals. These results support the notion that in-
creased STI1 levels found in human AD patient brain
tissue [29], may contribute to amyloidogenesis and para-
doxically increase toxicity in vivo.
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